The FDA is proposing to remove multiple GLP-1 drugs (a class of weight-loss and diabetes medicines) from a list of bulk ingredients that pharmacies are allowed to use to make cheaper compounded versions. This change could restrict pharmacies from making lower-cost copies and push patients toward buying more expensive brand-name versions.

• •FDA proposes excluding multiple GLP-1 RAs from the bulks list used for compounding
• •Move would restrict pharmacies from producing lower-cost compounded GLP-1 copies
• •Patients likely pushed toward higher-priced brand-name GLP-1 products